New York City - Events at Quotient Sciences

DCAT 2024

New York City | 18 March 2024 - 21 March 2024

Join our drug substance, drug product, and commercial manufacturing experts in New York City for DCAT Week 2024.

The annual Drug, Chemical & Associated Technologies Association (DCAT) event is a unique, multifaceted week of events that attracts key decision-makers from the pharma and biotech industry. 

Quotient Sciences' Drug Development Consultants will be participating in partnering meetings to learn more about your drug development needs and to provide an update on our expanded capabilities. Schedule a meeting with our team today to discuss your drug program's needs for 2024 and beyond.

or please register for our DCAT Seminar on March 20 here.

For more information or assistance, you can also contact us directly by emailing

New York City

Meet our Experts:

We look forward to meeting you at DCAT 2024.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Eleanor Row

Executive Director, Candidate Development Scientific Consulting

Eleanor Row has over 15 years of experience in the pharmaceutical and contract research environment working with multinational com...

About Eleanor
Dr. Vanessa Zann

Senior Drug Development Consultant

Dr. Vanessa Zann is a Senior Drug Development Consultant at Quotient Sciences. Vanessa has over two decades of industry experience...

About Vanessa

More insight from our experts:

Read More
Drug Product, Drug Substance, Translational Pharmaceutics Interview with Thierry Van Nieuwenhove: On Quotient Sciences' Growth and Role in Accelerating Drug Development By: Thierry Van Nieuwenhove
Read More
Oncology, Translational Pharmaceutics, Dr. Paul Quigley Insight from our experts: How Translational Pharmaceutics accelerates oncology clinical trials By: Dr. Paul Quigley
Read More
Oncology, Translational Pharmaceutics, John McDermott A Smarter Strategy for Optimizing Oncology Drug Products By: John McDermott
Read More